达到终点-话题@MedSci

#达到终点#

8篇内容 | 243人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1813851, encodeId=d99e181385125, content=<a href='/topic/show?id=29f09391e88' target=_blank style='color:#2F92EE;'>#达到终点#</a>, objectTitle=抗体药物偶联物Trodelvy显著改善三阴性乳腺癌患者的PFS：III期研究达到终点, objectType=article, longId=197187, objectId=f91619e187c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f91619e187c8, replyNumber=0, likeNumber=29, createdTime=2021-04-14, rootId=0, userName=snowpeakxu, userId=568152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f91619e187c8, moduleTitle=抗体药物偶联物Trodelvy显著改善三阴性乳腺癌患者的PFS：III期研究达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f91619e187c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813850, encodeId=e01f1813850c0, content=<a href='/topic/show?id=29f09391e88' target=_blank style='color:#2F92EE;'>#达到终点#</a>, objectTitle=小胖威利综合症：Soleno的二氮嗪胆碱控释片关键临床试验未达到终点, objectType=article, longId=195620, objectId=936519562096, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=936519562096, replyNumber=0, likeNumber=29, createdTime=2021-05-15, rootId=0, userName=snowpeakxu, userId=568152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=936519562096, moduleTitle=小胖威利综合症：Soleno的二氮嗪胆碱控释片关键临床试验未达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=936519562096)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813849, encodeId=b8b01813849cb, content=<a href='/topic/show?id=29f09391e88' target=_blank style='color:#2F92EE;'>#达到终点#</a>, objectTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, objectType=article, longId=189451, objectId=9d821894518e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d821894518e, replyNumber=0, likeNumber=42, createdTime=2020-05-06, rootId=0, userName=snowpeakxu, userId=568152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d821894518e, moduleTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d821894518e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813847, encodeId=22dd181384e58, content=<a href='/topic/show?id=29f09391e88' target=_blank style='color:#2F92EE;'>#达到终点#</a>, objectTitle=Takeda的Entyvio维多利珠单抗皮下制剂治疗克罗恩病，临床试验达到终点, objectType=article, longId=176042, objectId=e6681e604268, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6681e604268, replyNumber=0, likeNumber=42, createdTime=2019-09-22, rootId=0, userName=snowpeakxu, userId=568152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6681e604268, moduleTitle=Takeda的Entyvio维多利珠单抗皮下制剂治疗克罗恩病，临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6681e604268)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813844, encodeId=6e0718138443a, content=<a href='/topic/show?id=29f09391e88' target=_blank style='color:#2F92EE;'>#达到终点#</a>, objectTitle=BioMarin的血友病基因疗法III期临床达到终点，但其长期效应引起质疑, objectType=article, longId=167518, objectId=665116e51869, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=665116e51869, replyNumber=0, likeNumber=26, createdTime=2019-11-06, rootId=0, userName=snowpeakxu, userId=568152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=665116e51869, moduleTitle=BioMarin的血友病基因疗法III期临床达到终点，但其长期效应引起质疑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=665116e51869)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813848, encodeId=d0d518138485b, content=<a href='/topic/show?id=29f09391e88' target=_blank style='color:#2F92EE;'>#达到终点#</a>, objectTitle=酪氨酸激酶受体AXL抑制剂Bemcentinib联合Keytruda，用于晚期非小细胞肺癌的2期临床达到终点, objectType=article, longId=182592, objectId=625c1825922c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=625c1825922c, replyNumber=0, likeNumber=35, createdTime=2019-11-21, rootId=0, userName=snowpeakxu, userId=568152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=625c1825922c, moduleTitle=酪氨酸激酶受体AXL抑制剂Bemcentinib联合Keytruda，用于晚期非小细胞肺癌的2期临床达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=625c1825922c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813846, encodeId=ec9d18138463a, content=<a href='/topic/show?id=29f09391e88' target=_blank style='color:#2F92EE;'>#达到终点#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, objectType=article, longId=174364, objectId=c1da1e436402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1da1e436402, replyNumber=0, likeNumber=34, createdTime=2019-09-24, rootId=0, userName=snowpeakxu, userId=568152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1da1e436402, moduleTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1da1e436402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1813845, encodeId=2267181384537, content=<a href='/topic/show?id=29f09391e88' target=_blank style='color:#2F92EE;'>#达到终点#</a>, objectTitle=阿斯利康的酪氨酸激酶抑制剂Calquence在III期白血病试验中达到终点, objectType=article, longId=167833, objectId=1f1d16e833ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f1d16e833ae, replyNumber=0, likeNumber=0, createdTime=2019-07-01, rootId=0, userName=snowpeakxu, userId=568152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f1d16e833ae, moduleTitle=阿斯利康的酪氨酸激酶抑制剂Calquence在III期白血病试验中达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f1d16e833ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

达到终点

2020-05-29

snowpeakxu (审核中...)

前往app查看评论内容

#达到终点#

抗体药物偶联物Trodelvy显著改善三阴性乳腺癌患者的PFS：III期研究达到终点

2021-04-14

snowpeakxu (审核中...)

前往app查看评论内容

#达到终点#

小胖威利综合症：Soleno的二氮嗪胆碱控释片关键临床试验未达到终点

2021-05-15

snowpeakxu (审核中...)

前往app查看评论内容

#达到终点#

Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点

2020-05-06

snowpeakxu (审核中...)

前往app查看评论内容

#达到终点#

Takeda的Entyvio维多利珠单抗皮下制剂治疗克罗恩病，临床试验达到终点

2019-09-22

snowpeakxu (审核中...)

前往app查看评论内容

#达到终点#

BioMarin的血友病基因疗法III期临床达到终点，但其长期效应引起质疑

2019-11-06

snowpeakxu (审核中...)

前往app查看评论内容

#达到终点#

酪氨酸激酶受体AXL抑制剂Bemcentinib联合Keytruda，用于晚期非小细胞肺癌的2期临床达到终点

2019-11-21

snowpeakxu (审核中...)

前往app查看评论内容

#达到终点#

阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点

2019-09-24

snowpeakxu (审核中...)

前往app查看评论内容

#达到终点#

阿斯利康的酪氨酸激酶抑制剂Calquence在III期白血病试验中达到终点

2019-07-01

科室
- - 订阅+
  - 更多科室
工具
服务